Sun Pharmaceutical Industries has agreed to buy U.S. drugmaker Organon & Co for roughly $11.75 billion in cash, including debt. Under the deal, Sun Pharma will pay $14.00 per share for all outstanding Organon stock, giving it full ownership of the company. Organon was spun off from Merck in 2021 and focuses on three segments: women's health products, biosimilars (cheaper copies of complex biological drugs), and a portfolio of older established medicines sold largely in emerging markets. For Sun Pharma, already India's largest drugmaker by revenue, the deal marks a major step into the global specialty and biosimilars space. Organon's women's health franchise and biosimilar pipeline would significantly broaden Sun Pharma's product reach across the U.S. and international markets. At $11.75 billion, this ranks among the largest overseas acquisitions by an Indian pharmaceutical company. Investors will be watching how Sun Pharma plans to finance the all-cash deal and whether Organon's debt load affects the combined company's balance sheet going forward.
Flipkart will launch a food delivery pilot in Bengaluru by mid-August, charging restaurants a 10-11% commission compared to the 25-35% levied by Swiggy and Zomato. The move targets growing restaurant discontent with incumbent platforms and aims to drive daily engagement across Flipkart's 500 million registered users.
Maruti Suzuki crossed two lakh domestic units in July 2026 for the first time, recording 42.4% year-on-year growth. Total sales including exports and OEM supplies reached 2,41,421 units, with all passenger vehicle segments posting gains.
Air India's net loss more than doubled to ₹22,238 crore in FY26, prompting Tata Sons chairman N Chandrasekaran to extend the Vihaan.AI turnaround timeline from five years to as long as a decade.
UpGrad's all-stock acquisition of Unacademy, valued at Rs 1,955 crore, is set to close within three weeks after CCI clearance and near-complete investor sign-offs. The deal combines upGrad's upskilling business with Unacademy's test prep and medical education platforms, with Gaurav Munjal staying on as CEO.
